Search This Board: 
Created: 03/02/2020 03:25:51 PM - Followers: 46 - Board type: Free - Posts Today: 0

Outstanding Shares
Champignon Brands Inc.
Champignon Brand Inc. is a research-driven Company specializing in Mushroom Health Supplements that promote Holistic Health and Wellness.
The Canadian based company dedicated to the distribution of artisanal, medical mushrooms and associated CPGs.
The Champignon team believes that we enhance the health and wellness of Millions of consumers through the distribution of their premium, mushroom-infused suite of products.
Champignon Brands Inc is a member of The AMerican Mushroom Institue (AMI). The Institue is a national voluntary trade association representing the growers, processors and marketers of the cultivated mushroom in the United States and the industry worldwide. Membership is available to any person interested in the mushroom industry.
Categories of membership are grower, associate, professional and retiree.

100% Intellectual Property Ownership

Patents are the lifeblood of the biotech industry. Biotechnology is one of the most research-intensive industries, with companies in the sector typically investing between 40% and 50% of their revenues in research and development, compared to 13% in pharmaceuticals and 5% in the chemical industry. In many cases, IP rights can actually be the final product.

That's why Champignon Brands' ( SHRM ; SHRMF ) already impressive cache of pharmaceutical patents gives it a leg up in the competitive rush to claim market share in the nascent Psilocybin industry.

Normally, when you do clinical trials, the ideal is to own the resulting IP. Champignon is partnering with the University of Miami and Miller School of Medicine in its research work but will own 100% of the intellectual property, drug discovery, and resultant data.

Its Psilocybin Patent Portfolio will greatly help the company in the commercialization of GMO and vegan certified rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (PTSD), as well as substance and alcohol use disorders. Even better: It can license its patented formulations to other companies as it deems fit.

Champignon Brands Provides Update on Continuous Disclosure Review

Canada NewsWire

VANCOUVER, BC, Oct. 29, 2020

VANCOUVER, BC, Oct. 29, 2020 /CNW/ - Champignon Brands Inc. ("Champignon" or the "Company") (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF) continues to work diligently with the British Columbia Securities Commission (the "Commission") to address the ongoing continuous disclosure review and to coordinate the revocation of the existing cease trade order. The Company will provide guidance on definitive timing for revocation as soon as possible.

The Company has submitted all requested documentation to the Commission in connection with the review of financial statements of AltMed Capital Corp. ("AltMed") for the period ended June 30, 2020, and subject to review by the Commission expects to move forward with the finalization and public filing of these statements in short order. 

Continuous Disclosure Review History

On June 19, 2020, the Company was notified by the Commission that it would be subject to a continuous disclosure review. Such reviews are conducted by the Commission for the purposes of ensuring compliance with the continuous disclosure obligations imposed by applicable Canadian securities laws. In the case of the Company, this review relates to the Company's disclosure obligations since it became a reporting issuer on February 6, 2020 and includes a review of the disclosure surrounding acquisitions completed by the Company since that time.

In connection with the review, on June 19, 2020, the Commission issued a cease trade order suspending trading in the securities of the Company pending the filing of Business Acquisition Reports in connection with the acquisitions of Artisan Growers Ltd., Novo Formulations Ltd. and Tassili Life Sciences Corp. As a result of the cease trade order, trading in the common shares of the Company was suspended on the Canadian Securities Exchange.

The Business Acquisition Reports were filed by the Company on July 21, 2020, during which time the Company continued to work with the Commission to address comments received in the course of the disclosure review. As a result of the filing of the Business Acquisition Reports, on August 26, 2020, the Commission revoked the cease trade order previously issued on June 19, 2020. Concurrently with the revocation, the Commission issued a replacement cease trade order (the "Replacement Order"), pending the filing of a revised material change report (the "Material Change Report") in connection with the acquisition by the Company of AltMed.

Prior to the finalization of a revised Material Change Report, the Company is required to finalize the accounting treatment for the acquisition of AltMed, which includes compiling the financial statements of AltMed for the six-month period ended June 30, 2020 to meet disclosure requirements.

On October 27, 2020, the Commission issued an additional cease trade order pending the filing of the interim financial statements of the Company for the period ended June 30, 2020 (the "October Order").

The October Order is not expected to affect the review process or timing for the resumption of trading of the common shares of the Company as the reports required to be filed to satisfy the Replacement Order will address the outstanding items in the October Order. 

For further clarity, the Company anticipates that the Replacement Order and the October Order will be revoked at the same time.  The Company is working diligently with the Commission to ensure that the revocation of both the Replacement Order and October Order occurs as soon as possible.

Dr. Roger McIntyre
Chief Executive Officer


Champignon Brands | Storyboard Communications
Investor Relations, Toronto, Canada
Investor Line:  +1 (833) 375-9995 x611


Day Range:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts Free PlusOneCoin
No plusone'd posts yet. Be the first!
Post Subject
#658 Gomie 08/04/2022 06:33:46 PM
#657 Gomie 06/15/2022 11:23:06 AM
#656 Gomie 06/02/2022 04:20:37 PM
#655 Gomie 05/20/2022 04:28:23 PM
Re: Private placement and clinical trial Gomie 01/12/2022 10:06:04 AM
Absolutely! Juschilln 01/07/2022 08:53:44 AM
Ridiculous the bounce on this then back down GorillaDaddy 01/07/2022 12:10:26 AM
Will 2022 show a gain? willlbone 01/06/2022 03:49:02 PM
Fingers crossed! Good luck. Juschilln 12/16/2021 02:22:43 PM
Let’s hope brother — we bounced here a GorillaDaddy 12/16/2021 02:21:33 PM
I will put another $1K in and I'm Juschilln 12/16/2021 02:19:47 PM
Got 7000 shares, another 7000 then I'm full GorillaDaddy 12/16/2021 02:16:04 PM
I agree. Juschilln 12/15/2021 08:37:22 PM
$3200 investment down to $668 --- Ill throw GorillaDaddy 12/15/2021 08:30:37 PM
#643 Gomie 12/14/2021 11:20:17 AM
Braxia Scientific Featured in National News, W5 Canada's Time To Roll 10/24/2021 09:24:29 AM
I bought a lot more at .15 GorillaDaddy 10/15/2021 07:21:10 PM
Re: Ketamine treatment goes mainstream Gomie 10/14/2021 02:28:16 PM
#639 Re: KEtamine study results Gomie 09/30/2021 10:38:00 AM
#638 Re: Ketamine study results Gomie 09/30/2021 10:37:10 AM
#634 RE: clinical trial for depression Gomie 08/30/2021 10:31:07 AM
#633 Still dont get it, we aint into shrooms GorillaDaddy 07/06/2021 06:52:52 PM
#632 LOL!! Juschilln 06/03/2021 11:05:11 AM
#631 I don’t get it. My friends and I GorillaDaddy 06/03/2021 11:04:38 AM
#630 You can say that again! Wow! Juschilln 06/03/2021 06:58:57 AM
#629 Man, this is eating massive amounts of shit. GorillaDaddy 06/03/2021 12:17:18 AM
#628 I have had my eye on this company. monique14 06/02/2021 06:02:27 PM
#627 Should bounce off .32 T695 05/25/2021 04:53:22 PM
#626 SHRMF changed to BRAXF: Renee 05/20/2021 07:34:41 PM
#625 SHRMF - Have MMs OTCX & INTL been MACDaddy 05/17/2021 12:40:03 PM
#623 Braxia Scientific Opens First Ketamine Therapy Clinic in Mama_cass 05/13/2021 08:18:36 AM
#622 Dude — none ya’ll were here for so GorillaDaddy 05/08/2021 12:11:00 PM
#621 Mine is still showing in Schwab but I cnote420 05/06/2021 04:18:58 PM
#620 Appreciate that. Same with Ameriprise btw. I see Always wondering 05/05/2021 04:33:59 PM
#619 I guess I'll give TDA a call tomorrow Juschilln 05/05/2021 04:31:07 PM
#618 Same here, still looking Always wondering 05/05/2021 04:28:23 PM
#617 Is anyone else's account missing their SHRMF position?? Juschilln 05/05/2021 02:42:19 PM
#616 SHRMF: effective May 5,2021 Champignon Brands Inc. will Renee 05/04/2021 08:46:28 AM
#615 Remember fellas .30-.40 is where we buy. Bid DarkPool 04/29/2021 10:02:20 AM
#614 Another 42k naked short on ask. Look at DarkPool 04/28/2021 10:05:04 AM
#613 Lmfao. MMs are fuked.Our group has accumulated little DarkPool 04/28/2021 09:52:42 AM
#612 Hope u all took your profits and are DarkPool 04/28/2021 09:40:54 AM
#611 Gonna be alot chasing to get their shares DarkPool 04/26/2021 03:08:45 PM
#610 Squeeze imminent DarkPool 04/26/2021 12:32:01 PM
#609 No reason this low floater shouldn't be multiple dollars DarkPool 04/26/2021 10:33:50 AM
#608 Get some fellas. MMs ridiculous short and only DarkPool 04/26/2021 10:25:55 AM
#607 $SHRMF -In just out article on #Shroom stocks StevenCohen 04/25/2021 03:58:23 PM
#606 Of which 1.25 million was shorted by market DarkPool 04/23/2021 08:04:17 PM
#605 And another DarkPool 04/23/2021 02:51:01 PM
#604 Mindmed intraday high DarkPool 04/23/2021 02:18:03 PM
Post Subject